Results 21 to 30 of about 22,842 (183)

Expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in the lung tissue of obese mice and the effect of rosiglitazone on proinflammatory cytokine expressions in the lung tissue [PDF]

Korean Journal of Pediatrics, 2013
PurposeWe investigated the mRNA levels of peroxisome proliferator-activated receptor (PPAR)-α, PPAR-γ, adipokines, and cytokines in the lung tissue of lean and obese mice with and without ovalbumin (OVA) challenge, and the effect of rosiglitazone, a PPAR-
Seung Lok Ryu, Jae Won Shim, Duk Soo Kim, Hye Lim Jung, Moon Soo Park, Soo-Hee Park, Jinmi Lee, Won-Young Lee, Jung Yeon Shim   +8 more
doaj   +1 more source

ROSIGLITAZONE

International Journal of Clinical Practice, 2000
SUMMARYRosiglitazone, a potent thiazolidinedione oral antidiabetic agent recently approved in the US, differs structurally from pioglitazone and troglitazone (other approved thiazolidinediones), with greater PPARγ binding affinity and antihyperglycaemic potency in preclinical models.
openaire   +2 more sources

Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches

BMC Research Notes, 2009
Background A recent and provocative meta-analysis, based on few outcome events, suggested that rosiglitazone increased cardiovascular mortality and myocardial infarction.
Friedrich Jan O, Beyene Joseph, Adhikari Neill KJ   +2 more
doaj   +1 more source

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome

Iraqi Journal of Pharmaceutical Sciences, 2017
This study was designed to show the advantages of using the combination of metformin and rosiglitazone over using each drug alone in treatment of women with polycystic ovary syndrome (PCOS).Forty four women with PCOS were classified into 3 groups , group
Mohammed A.Taher, Waleed R. Sulaiman, Hillal Y. Al-Khairi   +2 more
doaj   +3 more sources

Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

PPAR Research, 2008
Although thiazolidinediones (TZDs) were found to be ligands for peroxisome proliferators-activated receptorγ (PPARγ), the mechanism by which TZDs exert their anticancer effect remains unclear.
Qing He, Ruiping Pang, Xin Song, Jie Chen, Huixin Chen, Baili Chen, Pinjin Hu, Minhu Chen   +7 more
doaj   +1 more source

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

BMC Pharmacology and Toxicology, 2017
Background Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM).
Pravesh Kumar Bundhun, Girish Janoo, Abhishek Rishikesh Teeluck, Feng Huang   +3 more
doaj   +1 more source

Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. [PDF]

PLoS ONE, 2008
BACKGROUND: Recently, the type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death.
Kitchener D Wilson, Zongjin Li, Roger Wagner, Patrick Yue, Phillip Tsao, Gergana Nestorova, Mei Huang, David L Hirschberg, Paul G Yock, Thomas Quertermous, Joseph C Wu   +10 more
doaj   +1 more source

Agnuside Stabilizes the Complex I Assembly Factor NDUFAF6 to Reinforce Mitochondrial Efficiency and Thermogenic Responsiveness

Advanced Science, EarlyView.
ABSTRACT Brown and beige adipocytes dissipate energy as heat, yet effective strategies to enhance their mitochondrial efficiency remain limited. Here, we identify Agnuside (AGN) as a selective stabilizer of the complex I assembly factor NDUFAF6. AGN directly binds cytosolic NDUFAF6, suppresses its ubiquitination, prolongs its half‐life, and facilitates
Qingwen Zhao, Li Xie, Qianzhuo Wang, Shuying Dai, Bei Li, Yingjuan Zhang, Zhe Sun, Yue Gao   +7 more
wiley   +1 more source

ROLE OF SOME COMPOUNDS IN AMELIORATING SOME HEMATOLOGICAL PARAMETERS AND LACTIC DEHYDROGENASE ACTIVITY IN RATS TREATED WITH ROSIGLITAZONE

Zagazig Journal of Pharmaceutical Sciences, 2010
The present study was carried out to evaluate some cardiovascular effect of Rosiglitazone, Nigella sativa, silymarin each alone and the combination of Rosiglitazone with either Nigella sativa or Silymarin in order to get the best combination to avoid the
Ahmed Hendawy , Mansour Zahra , Reham Hamza   +2 more
doaj   +1 more source